# Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia

> **NCT00686010** · PHASE2 · COMPLETED · sponsor: **Japan Tobacco Inc.** · enrollment: 198 (actual)

## Conditions studied

- Type II Hyperlipidaemia

## Interventions

- **DRUG:** Placebo
- **DRUG:** JTT-705 300mg
- **DRUG:** JTT-705 600mg
- **DRUG:** JTT-705 900mg

## Key facts

- **NCT ID:** NCT00686010
- **Lead sponsor:** Japan Tobacco Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-05
- **Primary completion:** 2001-01
- **Final completion:** 2001-06
- **Target enrollment:** 198 (ACTUAL)
- **Last updated:** 2008-05-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00686010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00686010, "Efficacy and Safety of JTT-705 300, 600 And 900mg in Comparison With Placebo in Patients With Type II Hyperlipidaemia". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00686010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*